HASBROUCK HEIGHTS, N.J., March 15 /CNW/ - Nymox Pharmaceutical
Corporation (NASDAQ: NYMX) announced today its financial results for the year
ended December 31, 2006. Product sales increased by 3.0% and amounted to
$437,440 for 2006, compared to $424,506 for 2005. Nymox reported a net loss of
$4,893,685, or $0.18 per share for the year ended December 31, 2006, compared
to $3,584,528, or $0.14 per share for 2005. 63% of the increase in net loss
was attributable to accounting requirements for stock option compensation. The
weighted, diluted average number of common shares at December 31, 2006 was
27,711,981, compared to 26,103,704 at December 31, 2005. Nymox currently has
$11.0 million in financing available from its most recent financing.
Nymox has developed NX-1207, an innovative new treatment for BPH. The
company's completed Phase 2 trial showed positive efficacy and safety results
for NX-1207. Overall, patients treated with NX-1207 showed mean improvement of
9.35 points in AUA Symptom Score values, the standard scale used to evaluate
BPH drugs and treatments. This improvement compares favorably to the 3.5 to 5
point reported in published studies of currently approved drugs for BPH and
reached statistical significance when compared to placebo. Subjects treated
with NX-1207 also showed an overall significant reduction in mean prostate
volume. The results of the trial demonstrated the excellent safety and side
effect profile of NX-1207. Subjects treated with NX-1207 had no serious side
effects. In particular, patients given NX-1207 had no (0%) significant sexual
More information about Nymox is available at www.nymox.com, email:
firstname.lastname@example.org, or 800-936-9669.
This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of 1995
that involve a number of risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and the actual results and
future events could differ materially from management's current expectations.
Such factors are detailed from time to time in Nymox's filings with the United
States Securities and Exchange Commission and other regulatory authorities.
For further information:
For further information: Nymox Pharmaceutical Corporation Roy Wolvin,